PubMed-indexed overlay journal for preprints with post-review manuscript marketplace (What is JMIRx?)


Edward Meinert, MA (Oxon), MSc, MBA, MPA, PhD, CEng, FBCS, EUR ING

JMIRx Med (ISSN 2563-6316), which has been accepted for indexing in PubMed and PubMed Central, is an innovative overlay journal to  MedRxiv and JMIR Preprints (other preprint servers are invited to join). JMIRx peer-reviews preprints and publishes their revised "version of record" with peer-review reports across a broad range of medical, clinical and related health sciences. Unlike the majority of JMIR journals, papers published in this journal do not require a digital health focus - in fact, most papers we published in the first months of the journal were related to COVID19, but we publish all research that qualifies for preprinting on MedRxiv

Conceived to address the urgent need to make highly relevant scientific information available as early as possible without losing the quality of the peer-reviewed process, this innovative new journal is the first in a new series of “superjournals”. Superjournals (a type of "overlay" journal) sit on top of preprint servers (JMIRx-Med serves MedRxiv and JMIR Preprints), offering peer-review and everything else a traditional scholarly journal does. Our goal is to rapidly peer review and publish a paper. All JMIRx Med papers must have originated as a preprint. 

All JMIRx Med papers are rigorously peer-reviewed, copyedited and XML-tagged. Accepted papers are published along with the related Peer Review Reports and Author Responses to Peer Review Reports, providing an additional layer of transparency to the scholarly publishing process. 

There is no Article Processing Fee directly paid by authors for this journal. JMIRx Med is envisioned as a diamond open access and Plan-P compliant journal, which enables Plan P member universities/institutions and funders to subsidize peer review of preprints and publishing in JMIRx Med. Individual PI-led labs, departments and universities can become institutional members, guaranteeing unlimited peer-review of preprints.

If you are not affiliated with a Plan P member organization, we encourage you to provide Plan P membership details to your administrator or sign up for a Principal Investigator (PI) level membership. Further details provided here.

For a limited time only, authors who opt-in during submission to receive PREreview or PeerRef community peer review for their preprint or refer us to their department head/librarian/funder contact will receive a membership-waiver and may publish the preprint in JMIRx Med at no cost to the author. Referral form provided here.

To submit a preprint to JMIRx, authors can self-nominate their existing preprints for publication (which is the equivalent to a traditional journal submission), using the minimalistic JMIRx-Med submission form that essentially only points to the preprint (the preprint needs to be unpublished and should not be under consideration by a journal).


Preprints that have already been peer-reviewed by third-party Plan P accredited peer-review services such as PREreview and PeerRef do not require further peer-review (at the editors' discretion). In the submission process, you can nominate your preprint for a PREreview journal club, which can be used in lieu of traditional peer-review.


For more details on other submission pathways (including for papers not in MedRxiv) and peer-review options see How to submit to a JMIRx journal.

For more information on JMIRx please also see our Knowledge Base article "What is JMIRx?".  



Recent Articles

Article Thumbnail

The postacute sequelae of COVID-19 (PASC) is a syndrome characterized by persistent COVID-19 symptoms or the onset of new symptoms following recovery from the initial or acute phase of the illness. Such symptoms often occur 4 or more weeks after being diagnosed with COVID-19. Although a lot of work has gone into understanding the long-term mental health effects of PASC, many questions related to the etiology and risk of this condition remain.

Article Thumbnail

The renin angiotensin system is composed of several enzymes and substrates on which angiotensin converting enzyme (ACE) 1 and renin act to produce angiotensin II. ACE1 and its substrates control blood pressure, affect cardiovascular and renal function, hematopoiesis, reproduction, and immunity. The increased expression of ACE1 has been observed in human monocytes during congestive heart failure and abdominal aortic aneurysm. Moreover, T lymphocytes from individuals with hypertension presented increased expression of ACE1 after in vitro stimulation with angiotensin II (ATII) with the highest ACE1 expression observed in individuals with hypertension with low-grade inflammation. Our group and others have shown that aging is associated with comorbidities, chronic inflammation, and immunosenescence, but there is a lack of data about ACE1 expression on immune cells during the aging process. Therefore, our aim was to evaluate the levels of ACE1 expression in nonlymphoid cells compared to lymphoid that in cells in association with the immunosenescence profile in adults older than 60 years. Cryopreserved peripheral blood mononuclear cells obtained from blood samples were used. Cells were stained with monoclonal antibodies and evaluated via flow cytometry. We found that ACE1 was expressed in 56.9% of nonlymphocytes and in more than 90% of lymphocytes (all phenotypes). All donors exhibited characteristics of immunosenescence, as evaluated by low frequencies of naïve CD4+ and CD8+ T cells, high frequencies of effector memory re-expressing CD45RA CD8+ T cells, and double-negative memory B cells. These findings, in addition to the increased C-reactive protein levels, are intriguing questions for the study of ACE1, inflammaging, immunosenescence, and perspectives for drug development or repurposing (Reviewed by the Plan P #PeerRef Community).


Preprints Open for Peer-Review

There are no preprints available for open peer-review at this time. Please check back later.

We are working in partnership with